Physician profile
William D Respess
NPI 1063401164
$79,335.65
in general payments reported to CMS, 2019-2025
13 companies · $51.33 in 2025
The $51.33 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $289 · 2021: $80.30 · 2022: $69K · 2023: $7,627 · 2024: $1,809 · 2025: $51.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $9,291 · Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $9,290.76 |
| Food and Beverage | $196.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $78,247.15 | 2022-2024 | Avenger Radial Head, +4 Stems |
| Horizon Therapeutics Plc | $480.55 | 2019-2023 | Krystexxa |
| In2bones USA, LLC | $255.67 | 2020-2022 | |
| Arthrosurface Incorporated | $175.50 | 2019-2020 | |
| Organogenesis INC. | $40.01 | 2021 | |
| Globus Medical, INC. | $36.42 | 2025 | Omnia, Senza |
| Tricoast Surgical Solutions LLC | $21.56 | 2024 | |
| Amgen INC. | $14.91 | 2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $14.38 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.95 | 2020 | |
| Integra Lifesciences Corporation | $12.12 | 2020 | |
| Nabriva Therapeutics, Plc | $11.94 | 2020 | |
| Paratek Pharmaceuticals, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Respess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.